JELMYTO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Jelmyto, and what generic alternatives are available?
Jelmyto is a drug marketed by Urogen Pharma and is included in one NDA. There are two patents protecting this drug.
This drug has nine patent family members in six countries.
The generic ingredient in JELMYTO is mitomycin. There are seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the mitomycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Jelmyto
A generic version of JELMYTO was approved as mitomycin by HIKMA on April 19th, 1995.
Summary for JELMYTO
| International Patents: | 9 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 89 |
| Clinical Trials: | 6 |
| Patent Applications: | 4,593 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for JELMYTO |
| What excipients (inactive ingredients) are in JELMYTO? | JELMYTO excipients list |
| DailyMed Link: | JELMYTO at DailyMed |
Recent Clinical Trials for JELMYTO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| City of Hope Medical Center | Phase 2 |
| Mayo Clinic | Phase 2 |
| National Cancer Institute (NCI) | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for JELMYTO
US Patents and Regulatory Information for JELMYTO
JELMYTO is protected by two US patents and two FDA Regulatory Exclusivities.
Patents protecting JELMYTO
Material and method for treating internal cavities
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Material and method for treating internal cavities
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting JELMYTO
INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)
Exclusivity Expiration: ⤷ Try a Trial
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urogen Pharma | JELMYTO | mitomycin | POWDER;PYELOCALYCEAL | 211728-001 | Apr 15, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Urogen Pharma | JELMYTO | mitomycin | POWDER;PYELOCALYCEAL | 211728-001 | Apr 15, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Urogen Pharma | JELMYTO | mitomycin | POWDER;PYELOCALYCEAL | 211728-001 | Apr 15, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Urogen Pharma | JELMYTO | mitomycin | POWDER;PYELOCALYCEAL | 211728-001 | Apr 15, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for JELMYTO
See the table below for patents covering JELMYTO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 2525777 | ⤷ Try a Trial | |
| European Patent Office | 2734187 | MATÉRIAUX ET MÉTHODE DE TRAITEMENT DE CAVITÉS CORPORELLES INTERNES (MATERIALS AND METHOD FOR TREATING INTERNAL BODY CAVITIES) | ⤷ Try a Trial |
| European Patent Office | 2525777 | MATÉRIEL ET PROCÉDÉ DE TRAITEMENT DE CAVITÉS INTERNES (MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES) | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2013011504 | ⤷ Try a Trial | |
| World Intellectual Property Organization (WIPO) | 2011089604 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
